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Atherosclerosis and ensuing cardiovascular disease (CVD) are major complications of
diabetes type 2. Atherosclerosis is a chronic inflammatory condition involving immuno-
competent cells of different types present in the lesions. Even though inflammation and
immune activation may be more pronounced in atherosclerosis in diabetes type 2, there
does not appear to be any major differences between diabetics and non-diabetics. Sim-
ilar factors are thus implicated in atherosclerosis-associated immune activation in both
groups.The cause of immune activation is not known and different mutually non-exclusive
possibilities exist. Oxidized and/or enzymatically modified forms of low-density lipoprotein
(OxLDL) and dead cells are present in atherosclerotic plaques. OxLDL could play a role,
being pro-inflammatory and immunostimulatory as it activates T-cells and is cytotoxic at
higher concentrations. Inflammatory phospholipids in OxLDL are implicated, with phos-
phorylcholine (PC) as one of the exposed antigens. Antibodies against PC (anti-PC) are
anti-atherogenic in mouse studies, and anti-PC is negatively associated with development
of atherosclerosis and CVD in humans. Bacteria and virus have been discussed as potential
causes of immune activation, but it has been difficult to find direct evidence supporting this
hypothesis, and antibiotic trials in humans have been negative or inconclusive. Heat shock
proteins (HSP) could be one major target for atherogenic immune reactions. More direct
causes of plaque rupture include cytokines such as interleukin 1β (IL-1β), tumor necrosis fac-
tor (TNF), and also lipid mediators as leukotrienes. In addition, in diabetes, hyperglycemia
and oxidative stress appear to accelerate the development of atherosclerosis, one mech-
anism could be via promotion of immune reactions. To prove that immune reactions are
causative of atherosclerosis and CVD, further studies with immune-modulatory treatments
are needed.
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BACKGROUND
Type 2 diabetes represents a major and growing problem through-
out the world, not only in so-called developed countries. In
addition to nephropathy and microvascular disease, cardiovas-
cular disease (CVD), and accelerated atherosclerosis often occur
in diabetes, both type 1 and 2 (1–3). The main focus of this
review is immune activation in atherosclerosis, especially in type
2 diabetes.
The link between type 2 diabetes and inflammation is well
established, and there are signs of chronic inflammation in both
diabetes and insulin resistance (IR), a typical feature of type 2
diabetes (4). Also in atherosclerosis and CVD, chronic inflamma-
tion is a major feature, and in atherosclerosis, activated immune
competent cells such as T-cells and antigen-presenting cells, are
abundant in lesions (5).
Even though inflammation and size of the necrotic core may be
increased in atherosclerosis in diabetes (6, 7), there was no differ-
ence in the prevalence of macrophages, lymphocytes, and overall
inflammation in plaque or in the atherosclerotic cap between dia-
betics and non-diabetics according to the largest study in this area
(8). It thus appears that there is no known fundamental difference
between the immune activation and inflammation present in
atherosclerosis among non-diabetics as compared to diabetics.
Still macrophages and surface thrombi may persist longer after
ischemic symptoms in diabetes, which could contribute to the
increased risk of recurrent CVD in this condition (8) and risk fac-
tors as hyperglycemia naturally play a special role. In this review, I
therefore discuss immune activation in atherosclerosis in general
and in diabetes type 2 in the same context.
Acute inflammatory response developed from an evolution-
ary point of view most likely to protect against pathogens and to
repair tissue damage, which could be caused also by trauma. The
classic symptoms of acute inflammation – pain, swelling, redness,
heat, and decrease of function – were described already in Hip-
pocratic medicine. When acute inflammation is not resolved, but
instead persists and becomes chronic, it can become a major prob-
lem. Indeed chronic inflammatory conditions represent a major
disease burden in the western world,and increasingly,also in devel-
oping countries (9). Examples of chronic inflammatory diseases
include rheumatic diseases such as rheumatoid arthritis (RA) and
systemic lupus erythematosus (SLE); atherosclerosis and its major
consequence, CVD including myocardial infarction (MI), acute
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coronary syndrome (ACS), claudication, and stroke; Alzheimer’s
disease; diabetes type 2; increased IR and even abdominal obesity
and osteoarthritis have inflammatory components (9).
Associations between these conditions are well known. For
example, type 2 diabetes is a major risk factor for atherosclerosis
and CVD (together with smoking, hypertension,dyslipidemia,age,
and male sex) (10). Alzheimer’s disease and atherosclerosis and/or
CVD have some risk factors in common (11) and smoking is a risk
marker for RA in addition to well known effects in CVD (12). It has
also become clear that there are associations between rheumatic
diseases and atherosclerosis/CVD, especially in SLE (13). Also in
RA, there is an increased risk of CVD according to many reports,
and a recent meta-analysis imply that atherosclerosis per se is more
prevalent in patients in RA (13–15). It is interesting to note that
there are reports which also describe an increased risk of type 2
diabetes in RA (16).
Anti-inflammatory treatments have improved the prognoses
of many patients in chronic inflammatory conditions, the most
notable example being biologics such as tumor necrosis fac-
tor (TNF)-inhibitors in RA and other autoimmune conditions
(9). There is therefore an apparent need to evaluate targeted
anti-inflammatory and immunomodulative treatments in other
chronic inflammatory conditions.
An interesting possibility would be that biologics such as TNF-
inhibitors could be therapeutically effective in atherosclerosis and
diabetes type 2 and their complications. However, this does not
appear to be the case to any significant degree. Although systemic
blockade of TNF has an anti-cachectic effect in RA patients, the
data on anti-TNF effects of IR are conflicting, depending on dis-
ease severity and degree of inflammation (17–19). Still, a recent
case report indicates that treatment with a novel T-cell inhibitor
had a dramatic effect on IR in RA (20).
As discussed in an editorial (14), it is interesting to note
that inflammatory nature of atherosclerosis was known already
180 years ago, reported by the famous Austrian pathologist K.
Rokitansky. R. Virchow confirmed these findings somewhat later,
and the ensuing debate between these two giants in the history of
medicine is of interest also now (21, 22). Rokitansky argued that
atherosclerosis is secondary to other disease processes and phe-
nomena, while Virchow supported the view that inflammation in
atherosclerosis is a primary pathogenic factor (21, 22). Both could
be right, since atherosclerosis is nowadays recognized as an inflam-
matory process, and could be secondary to other inflammatory
conditions.
A role of the immune system in atherosclerosis, with or with-
out background of diabetes type 2, has been suggested since the
1980s, when activated T-cells were detected in human athero-
sclerotic lesions (23). Since then, an array of data indicate that
immune activation is a major feature of and plays a role in athero-
sclerosis, and also that immunomodulation to ameliorate disease
development could be an interesting possibility (10, 24, 25).
At an early stage of atherosclerosis, macrophages accumulate
and become filled with lipids, mainly derived from modified forms
of low-density lipoprotein (LDL). These lipid-filled macrophages
develop into foam cells, and subsequently, these and other cells
die, creating a necrotic core of cell debris. An organized apoptotic
clearance, is thus not effective in advanced atherosclerotic lesions.
Also lymphocytes, especially T-cells, are common at a very early
stage of disease development. In the 1990s, it was demonstrated
that immunomodulation can change the course of atherosclerosis
development; while administration of heat shock protein 60/65
accelerated atherosclerosis development (26), immunization with
oxLDL, had the opposite effect (27).
However, it should be noted, that there may be important
differences between animal models and human disease in this
context (28). Even though mouse models of atherosclerosis have
very much increased our understanding of atherosclerosis it is
still interesting to note that there may be problems with trans-
lating mouse data to humans. For example, lipid levels are strik-
ingly much higher in mice models, and another problem is that
it is difficult to mimic human CVD in animal models, includ-
ing mice models (29, 30). In this review, I have therefore cho-
sen to emphasize data on immunity and atherosclerosis which
are derived from human studies, including ex vivo and cohort
studies.
As discussed in a previous review (24), available evidence indi-
cates that atherosclerosis per se is a normal part of human aging,
though its complications may not be part of the normal aging
process, at least not to the same extent.
A direct causative role played by T-cells is suggested by
animal experiments, with transfer of beta(2)-glycoprotein I-
reactive lymphocytes, which enhanced early atherosclerosis in
LDL receptor-deficient mice (31). Further, CD4+ T cells reac-
tive to modified low-density lipoprotein aggravate atherosclero-
sis (32). An immunomodulatory role of T-cells is suggested by
experiments where regulatory T cells suppress immune activa-
tion and thereby inhibit atherosclerosis (33). Interestingly, also
NK T-cells may play a role in this context since CD1d-dependent
activation of NKT cells aggravates atherosclerosis (34). Relatively
little is known about the role of T-cells in human atheroscle-
rosis, but it is interesting to note that Th17/Th1 imbalances
have been reported, which may be related to plaque rupture
(35, 36). Interestingly, data in humans and mice provide sup-
port for the concept that TH17 cells induced upon TGF-b sig-
naling promote the development of cap structures in athero-
sclerotic plaques and the role of T-cells could depend on the
local activation pattern and milieu (37). Clearly, the role of T-
cells in plaque rupture is complicated. Further, subsets of T-
lymphocytes with pro-atherogenic and plaque-destabilizing prop-
erties are increased in diabetes type 2 and associated with a worse
CVD-outcome (38).
During recent years, a more detailed picture also of other
inflammatory and/or immune competent cells has emerged
from in vivo and other experimental studies, which need to be
corroborated in human disease.
One example is dendritic cells (DC) which are specialized
antigen-presenting cells, which may play an important role in the
initiation and progression of atherosclerosis (39). DC are present
in immature forms in the arterial wall and become activated dur-
ing atherogenesis. In human atherosclerosis, DC are present both
at an early stage (40) and late stage, with higher numbers in
vulnerable plaques (41). Similar findings have been reported in
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mice, where DC may promote atherogenesis (42). Further, DC
and T-cells co-localize in plaques (43).
Monocytes/macrophages are present in lesions at different
stages of atherosclerosis. Macrophages play a major role in inflam-
matory responses and may alter their phenotype which may vary
on a scale, from pro-inflammatory M1 to anti-inflammatory M2
macrophages. Interestingly, even though the whole spectra of
macrophages are present in lesions, including the relatively inert
and surprisingly long lived macrophage-derived foam cells, M1
cells are prevalent in the vicinity of plaque rupture (44, 45).
Another cell type common in atherosclerotic lesions with
inflammatory and potentially immune-modulatory properties is
mast cells (46). A significant role played by this cell type in ather-
osclerosis and its complications is suggested by a recent report,
where it is demonstrated that intraplaque mast cell numbers
associate with future cardiovascular events (47).
Even though some B-cells,neutrophils, and NK-cells are present
in lesions, it is not known to what extent they play a major
role (10).
The role of the immune system in human atherosclerosis with
or without background of diabetes type 2 is less defined as com-
pared to the relevant animal models. T-cell reactive to OxLDL
and related lipids are present in blood and atherosclerotic plaques
(48, 49), patients with autoimmune diseases have increased ath-
erosclerosis (13), and aspects of humoral immunity as natural
antibodies against phosphorylcholine (PC) and other antigens
are associated with atheroprotection (50). Humoral immunity
has been shown to have pathogenic consequences in type 1 dia-
betes, triggered by immune complexes containing oxidized forms
of LDL (51).
Available data thus imply that the immune system plays a
major role in atherosclerosis, which could be seen as a chronic
inflammatory disease or disease process. Interestingly, also dia-
betes, IR abdominal obesity, and the metabolic syndrome also
have important inflammatory components.
DIABETES AND CAUSES OF IMMUNE ACTIVATION IN
ATHEROSCLEROSIS
The key question herein is to elucidate what is the direct cause of
the immune reactions in atherosclerosis, in general and in diabetes,
and also how the inflammatory disease process can be influenced.
There are several major hypotheses, non-mutually exclusive.
OXIDATION AND OTHER MODIFICATIONS OF LDL AND OTHER MOIETIES
Low-density lipoprotein can be modified by oxidation and/or
enzymatic modification phospholipases being one example. LDL
is also normally present in tissues as the intima of arteries, where
it can bind to the proteoglycan matrix especially after modifica-
tion. This binding is thought to be an early event in atherogenesis
according to the “response to retention” hypothesis (52, 53).
Oxidized low-density lipoprotein has pro-inflammatory and
immune-activating properties, activating endothelial cells, mono-
cytes/macrophages, and T cells (49, 54, 55). OxLDL also toxic
at higher concentrations and an important feature of athero-
sclerotic lesions, perhaps somewhat understudied, is the abun-
dance of dead cells. It is thus possible that OxLDL is one cause
of such cell death (49, 54, 55). Enzymatically modified LDL
could play a major role, and PLA2, which causes such modifi-
cation, is expressed in both normal arteries and atherosclerotic
lesions (56) and can induce activation of DC (57). Inflamma-
tory phospholipids such as lysophosphatidylcholine (LPC) and/or
platelet activating factor (PAF)-like lipids cause much of OxLDL:s
effects which can occur through the PAF-receptor (58–61) or
other mechanisms including Toll-like receptor- and scavenger
receptor-interaction (62, 63).
In general oxidized phospholipids (OxPL) are implicated in
immune reactivity in atherosclerosis, and could be derived from
LDL-modification but also from cell membrane changes. Such
oxPL include LPC, and often, a shortened sn-2 position in the
fatty acid moiety serves as a danger-associated molecular patterns
(DAMP). Oxidation turns OxPLs into markers of modified self,
which are recognized by both soluble and cell bound receptors such
as scavenger receptors, natural antibodies, and also C-reactive pro-
tein (CRP). The common theme in these different system is likely
to be removal of senescent and dead cells, but also oxidized or oth-
erwise modified lipoproteins. This has been described in several
recent publications (62, 64–69).
Another important example of DAMP, in addition to PC and
oxPL epitopes, is malonyl-dialdehyde (MDA) which is also gen-
erated during LDL-oxidation. MDA forms adducts on proteins,
carbohydrates, and DNA (63).
Other compounds which could be implicated as atherogenic
in OxLDL are modified and/or oxidized forms of apoB and
cholesterol. Such modified compounds may play a role but the
underlying mechanisms need to be better defined (63, 70). Clinical
studies support the hypothesis of inflammatory phospholipids as
causes of atherosclerosis, whereas levels of OxLDL are raised in the
metabolic syndrome (71), in hypertension (72) and in established
type 2 diabetes (73). Further, high levels of MDA-LDL in isolated
immune complexes predict future MI and acute CVD events in
patients with type 2 diabetes (74).
Many epidemiological studies demonstrate that smoking is
associated with atherosclerosis and CVD (75, 76) and animal
experiments demonstrate that smoking promotes atherogenesis
(77–79). Somewhat surprisingly, underlying mechanisms are not
fully clarified. Still, one mechanism is smoking-induced increased
lipid-oxidation (80) and closely related to this, oxidative stress
(81). Smoking is associated with systemic and local inflammation
with raised levels of pro-inflammatory cytokines and cells, in par-
ticular in chronic obstructive pulmonary disease (82), which could
play a role also in atherosclerosis.
Additionally, several factors appear to be diabetes-specific and
able to further aggravate atherosclerosis (and CVD) among diabet-
ics. One major such factor is reduction of endothelial nitric oxide
(NO)-levels, leading to deterioration of endothelial function, an
early sign of vascular problems and increased risk of atheroscle-
rosis and CVD. Hyperglycemia per se leads to increased levels of
reactive oxygen species, which in turn inactivate NO and thus
impair endothelial function. One common denominator is the
formation of advanced glycation end products (AGEs) which have
pro-inflammatory and potentially atherogenic properties (83–88).
Interestingly, atherosclerosis is suppressed by the soluble receptor
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for AGEs in an animal model (89). Also susceptibility of LDL and
its subfractions to glycation could play a role, in diabetes type
2 (90) AGE-products of LDL are able to generate autoantibod-
ies, which on the other hand appear to have pro-inflammatory
properties (91). Another interesting connection between AGEs
and OxLDL are previous findings where AGEs initiate LDL oxida-
tion (92). Further, increased oxidation of LDL in diabetes could
promote atherogenesis (73, 93).
Other potential underlying factors are present in type 2 dia-
betes, but where the connection to immune reactivity in athero-
sclerosis is less clear, and thus not a focus herein. These include
increased circulating free fatty acids in patients with abdominal
obesity, which could be atherogenic by decreasing HDL-levels,
increasing levels of small dense LDL and also by a negative effect
on endothelial function (3, 94). Other mechanisms include effects
on smooth muscle cells, such as induction of apoptosis and
thus plaque instability (95) and also a hypercoagulative state by
alterations in platelet function (96).
AUTOANTIBODIES AND IMMUNE COMPLEXES RELATED TO
PHOSPHOLIPID EPITOPES AND OxLDL
An interesting possibility is that immune complexes containing
OxLDL could contribute to vascular damage by promoting inflam-
mation and atherosclerosis, which has been reported in type 2
diabetes (97, 98). In addition to oxLDL, also MDA-LDL and AGE-
product-modified LDL induce immune responses in humans (99).
The role of antibodies against these different forms of modified
LDL is less clear, and varies in different studies: both negative and
positive associations have been described. This could depend on
different methods used, different degrees of oxidation and also on
different immunoglobulin subclasses and isotypes. On the other
hand, the antigenic constitution of immune complexes formed
with modified forms of LDL and their corresponding antibod-
ies may influence their pathogenicity, as suggested by the recent
observation that high levels of highly oxidized forms of LDL
(MDA-LDL) in isolated IC predict future MI and acute CV events
in patients with type 2 diabetes (74).
It is also possible that there are differences between mouse and
man which could be the basis for the conflicting views about the
pathogenic or protective role of the antibody response to modified
forms of LDL (100, 101).
Another type of antibodies that has attracted attention are those
against PC (anti-PC), which are often considered as“natural”anti-
bodies. We have reported in several publications that anti-PC is
a protection marker for atherosclerosis development and CVD,
in different populations, both healthy individuals, ACS patients,
and patients with SLE or RA (50, 102–107). Animal experiments
also support a protective role of anti-PC. Immunization with
pneumococci containing PC induced a decrease in atherosclero-
sis development in a mouse model in parallel with an increase in
anti-PC, among other antibodies (108). Passive and active immu-
nization raising anti-PC levels decrease atherosclerosis in mouse
models (109, 110).
Human anti-PC could be anti-atherogenic and decrease risk
of CVD by anti-inflammatory effects (107), inhibition of oxLDL-
uptake through scavenger receptors (111) and inhibition of LPC-
induced cell (112). In mouse models, the anti-inflammatory
effect of anti-PC was confirmed, and facilitating phagocytosis was
reported as one mechanism. Anti-PC antibodies bind dead and
dying cells, enhancing their phagocytosis and clearance (113). Fur-
ther investigations are necessary to determine whether the data
generated in animal models translates to human medicine.
A Western life style could play a role to influence anti-PC lev-
els, and one underlying factor could be infections which are not
prevalent in developed countries (114, 115). Gluten in the diet
could also play a role being a novel component of human diet from
an evolutionary point of view (116). The heritability of anti-PC
is 37%, allowing also for genetic factors (117). In line with these
findings, a recent report indicates that antibodies against reac-
tive a-dicarbonyls such as methylglyoxal (MGO) are negatively
associated with atherosclerosis development among patients with
diabetes type 2. This finding suggests an additional role played
by diabetes type 2 immune reactivity in atherosclerosis devel-
opment as compared to the general population (118). Still, it is
interesting to note that MGO-LDL is only weakly immunogenic
in humans (119). Clearly, further research is needed to clarify
the role by AGE-recognizing antibodies in diabetes type 2 and
atherosclerosis.
A potential role of epigenetic changes in both atherosclero-
sis/CVD and type 2 diabetes is not the topic of this review, though a
very interesting subject. One can not exclude that epigenetic mech-
anisms may influence immune mechanisms in both these condi-
tions. In an intriguing study, it was recently demonstrated that
in an atherosclerosis mouse model, maternal immunization with
oxidized LDL affects in utero programing of both atherosclerosis
and IR and type 2 diabetes, promoting protection against devel-
opment of these conditions (120) Whether this can be translated
to humans also remains to be demonstrated.
HEAT SHOCK PROTEINS
Antibodies against heat shock proteins (HSPs), especially
HSP60/65 but also others like HSP70 and HSP90 have been
described as potential causes of atherosclerosis and CVD. HSPs
are immunogenic, and T-cell clones recognizing HSP60 are present
in atherosclerotic plaques (121, 122). HSPs may activate immune
reactions through cross-reactivity with HSP from microorgan-
isms as bacteria. This is supported by both clinical data with
associations between antibodies against HSP60/65 and atheroscle-
rosis, and experimental data where immunization with HSP 60/65
increases atherosclerosis in an animal model (26, 123).
We hypothesized that hypertension possibly could cause and
immune reaction and inflammation in arteries by induction of
HSP 60/65, which are also induced by oxLDL (124, 125) and in
principle, in conditions such as diabetes, where LDL-oxidation
is implicated, this could further enhance the progression of
atherosclerosis.
INFECTIONS
Infections have since long been hypothesized to be a cause of
atherosclerosis. Many pathogenic candidates have been proposed,
one not excluding another.Chlamydophila pneumoniae (CP); peri-
odontal organisms including Porphyromonas gingivalis (PG) and
Aggregatibacter actinomycetemcomitans (AA); Helicobacter pylori
(HP) and Cytomegalovirus (CVM) are among the most promising
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candidates, since they are present in plaques, promote athero-
sclerosis in animal studies, and have associations with disease in
humans (126).
Early studies demonstrated presence of CP in atheroscle-
rotic plaques (127) and that antibodies against CP were asso-
ciated with CVD (128–130) but later also negative studies were
published (126).
However, treatment with CP-targeting antibiotics had no effect
on atherosclerosis (131–133). This clearly argues against CP as
a causative agent, though there could be other explanations, for
example, CP is difficult to reach within the plaque and thus it is
still possible that at the earlier stages of CP-infection antibacterial
treatment could be beneficial (126).
Periodontal pathogens, as PG and AA, are also interesting
pathogenic candidates. The association with periodontitis and
CVD/atherosclerosis has been debated since there are confounders,
including social ones,which may be difficult to control for. A recent
statement from the American Heart Association supports an inde-
pendent association between periodontal disease and atheroscle-
rosis, but available data do not prove causation, even though it is
interesting that intervention does decrease systemic inflammation
and improves endothelial function (134).
Still it is interesting that periodontitis and diabetes could
be related to each other, and in principle, periodontitis could
be diabetogenic and then also increase the risk of athero-
sclerosis and CVD, while diabetes could increase the risk of
periodontitis (135–137).
An inherent problem with viral infections such as CMV from
the Herpes virus group is that they are very common, thus making
the interpretation of any associations with diabetes, atherosclero-
sis or CVD complicated. It may be that certain patients subgroups
that are prone to accelerated atherosclerosis and CVD, as it is seen
for example after organ transplantation, CMV infection plays an
important role (138). CMV is present in atherosclerotic lesions in
many but not all studies (126), but also in healthy arteries (139) so
in principle CMV could be just an innocent by-stander. However,
CMV induces migration of arterial smooth muscle cells in vitro,
suggesting potential pro-atherogenic mechanisms (140).
Helicobacter pylori infection, causing gastritis and gastric ulcer,
may be implicated as supported by indirect evidence, where reduc-
tion of CVD after eradication of HP was reported (126, 141).
However, no viable HP had been isolated from atherosclerotic
plaques, and mouse experiments in general do not support a
pathogenic role of HP in atherosclerosis (142).
Other pathogens including HIV, EBV, influenza virus,
Mycoplasma pneumoniae and Streptococcus pneumoniae have also
been discussed, but as of yet there is no conclusive causative
evidence available (126). Borreliosis caused by spirochetes, is inde-
pendently associated with CVD, although little is known from
atherosclerosis-related experimental studies (143).
It is not clear if infections on the diabetic background con-
tribute more to atherosclerosis, but it is interesting to note that an
increased rate of infections with Chlamydia pneumoniae has been
reported in patients with diabetes type 2 (144).
Taken together, even though the infection hypothesis in ather-
osclerosis with or without diabetes type 2 is very interesting and
is supported by circumstantial evidence, there is still little direct
evidence of a potential causative or pathogenic role of microorgan-
isms in CVD/atherosclerosis. However, we can not exclude a pos-
sibility that infectious agents act in concert with diabetes-specific
factors to promote atherosclerosis.
Infections could also be of importance indirectly. Many
pathogens are present in lesions, and could start or promote an
ongoing local inflammatory process which could lead to increased
atherosclerosis and, in principle, also to CVD and plaque rupture –
at such sites, the local inflammation appears to be especially strong
(5). Also the total infectious burden is associated with increased
atherosclerosis and CVD, and the risk of infection is raised in
diabetes, especially when blood glucose levels are not well con-
trolled. Platelet aggregation and endothelial dysfunction, could
also influence atherogenesis in this context (126, 145).
OTHER TYPES OF IMMUNE ACTIVATION IN DIABETES TYPE 2 AND
ATHEROSCLEROSIS
Another potential link between atherosclerosis and diabetes type
2, and thus also hyperglycemia and metabolic dysfunction, is pro-
vided by a recent study, where NKG2D, an immune-activating
receptor expressed by different types of immune cells was tested
(146). The authors reported that blocking NKG2D in apolipopro-
tein E-deficient (apo E−/−) mice led to a dramatic reduction in
plaque formation, suppressed systemic and organ-specific inflam-
mation, and improved abnormal metabolic conditions. Thus the
NKG2D/ligand interaction could drive both: inflammation related
to metabolic dysfunction/diabetes type 2 and atherosclerosis. Fur-
ther, the molecules and pathogens discussed earlier such as OxLDL,
HSPs, AGEs, and infectious agents, could upregulate NKG2D on
different cell types, which in turn can activate T-cells, NK, and
NKT cells and thus promote atherosclerosis; also other cell types as
endothelial cells could produce pro-atherogenic factors, including
cytokines (146).
It is well known that inflammation is a link between IR, obesity,
and diabetes. Further abdominal obesity and IR are classic features
of type 2 diabetes (147).
There are many examples of links between inflammation in
other conditions and atherosclerosis. Periodontitis is also a sys-
temic inflammatory condition, which is more frequent in patients
with diabetes, could increase the risk of atherosclerosis and CVD
also indirectly (137).
Raised levels of CRP is a risk marker for atherosclerosis and
CVD in many studies, though it is not clear if CRP is either pro-
tective or detrimental for disease development. Cytokines as IL-6
and raised systemic levels of OxLDL are other examples of pro-
inflammatory molecules that are associated with increased risk of
CVD and atherosclerosis (10). Another group of inflammatory
compounds that are present in advanced atherosclerotic plaques
are lipid mediators, such as leukotrienes (148, 149).
Another example of associations between systemic inflamma-
tion and atherosclerosis and CVD is a number of autoimmune
diseases. The evidence is strongest for SLE, where the risk of CVD
is very high (13, 14, 150). Also in RA and other types of autoim-
mune conditions, atherosclerosis is increased according to many
studies including a recent meta-analysis (13–15).
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TREATMENT AGAINST INFLAMMATION AND IMMUNE
ACTIVATION TO AMELIORATE ATHEROSCLEROSIS,
DECREASE RISK OF CVD, ESPECIALLY IN DIABETES
OPTIMAL DIABETES TREATMENT
Since diabetes type 2 is an inflammatory condition, first and fore-
most, control of the disease itself is likely of major importance for
amelioration of pro-atherogenic inflammation and immune reac-
tions. The specific optimal range of glycemic control in relation
to CVD and atherosclerosis is still debated (151). This is similar
to the situation in rheumatic diseases, where at least for RA, the
risk may be similar to that in type 2 diabetes and where disease
controls appears to be of importance (13).
STATINS
Statins were developed to treat hyperlipidemia and are often
used in diabetes, though there is still some controversy about
their exact role in this condition (152). Interestingly, statins have
additional anti-inflammatory effects rather than simply decreas-
ing cholesterol levels, which could be of major importance in
atherosclerosis and CVD, not least in diabetic patients. These
properties could be seen as “side-effect” of HMG CoA-reductase
inhibition. Interestingly, statins have immunomodulatory proper-
ties, such as impairment of CD1d-mediated antigen presentation
through the inhibition of prenylation (153) and decreasing MHC
class II interaction with antigen (154). Further, the lipid-lowering
effect of statins could by itself influence the immune reactions to
LDL-related antigens, since a decrease in LDL-levels is likely to
decrease also exposure of the immune system to modified forms
of LDL, thus reducing the intensity of the corresponding immune
response.
The Jupiter study demonstrated that statin treatment may be
beneficial for individuals with increased high sensitivity CRP but
normal LDL and it is possible that the beneficial effects of statins
to some extent are in fact caused by their anti-inflammatory and
immune-modulatory properties (155, 156).
ANTI-INFLAMMATORY TREATMENT
Even though the major focus of this review is immune activation
it is still interesting to discuss this in the context of inflamma-
tion in general, especially in relation to treatment. There is as
yet no established anti-inflammatory treatment of atherosclero-
sis or CVD, with or without diabetes. There are several inter-
esting possibilities that are currently being investigated. In RA,
treatment with methotrexate weekly is a very common sched-
ule, and a recent meta-analysis demonstrate that the risk of
CVD is decreased in patients with RA treated with methotrexate
(157). Animal studies show that methotrexate decreases athero-
genesis (158). In the cardiovascular inflammation reduction trial
(CIRT) low dose methotrexate (target dose 20 mg/week) is tested
for reduction of CVD events among post-MI patients with dia-
betes or metabolic syndrome (156). There are different opinions
about whether biologics as anti-TNF are beneficial from a car-
diovascular point of view, though a recent study where decrease
of CVD was reported in RA adds support to this possibility
(159, 160). The Canakinumab Anti-Inflammatory Thrombosis
Outcomes Study (CANTOS) investigates interleukin-1β (IL-1β)
inhibition and reduced risk of MI, stroke, and CVD in stable
coronary artery disease patients with persistent elevations of CRP
(≥2 mg/L) (156, 161).
Other interesting anti-inflammatory treatments could be inhi-
bition of inflammatory lipid mediators as PAF (162). Annexin A5
is anti-thrombotic plasma protein, which is anti-inflammatory,
inhibits atherosclerosis development and improves endothelial
function in a mouse model (163). Annexin A5 could thus be a pos-
sible therapy candidate. Inhibition of phospholipases as treatment
in patients after ACS are currently in trials (164).
IMMUNOMODULATORY THERAPY
Studies in mid-90s demonstrated that immunization with mod-
ified forms of LDL ameliorated atherosclerosis in animal mod-
els (27), providing initial evidence for immunomodulation as a
potential treatment against atherosclerosis. One line of treatment
is to target the apoB components which decreases atherosclerosis
development in animal models (70, 165). However, such treatment
did not show positive expected effect in humans (166), though the
possibility that the end points used in this study where not optimal
cannot be excluded.
Another possibility is that the phospholipid moiety on OxLDL
could be the basis of immunomodulation, one example being PC.
This is supported by clinical studies, animal and in vitro experi-
ments (50). As discussed, mechanisms include anti-inflammatory
(107, 167), inhibition of cell death (112), and decreased uptake
of oxLDL in macrophages (105). Further, administration of
immunoglobulins has shown promising results in animal studies
(168). Another interesting possibility is to ameliorate atheroscle-
rosis by modulating immune reactions against HSP (169, 170).
SUMMARY AND CONCLUSION
Taken together, atherosclerosis and ensuing CVD represents major
health problems in the developed world and especially so in
patients with diabetes, where macro-vascular complications is a
common problem. It has become clear that atherosclerosis on
a background of diabetes or without is a chronic inflammation
characterized by presence of activated immune competent cells
throughout the lesions. Atherosclerosis in diabetes, though accel-
erated, does not seem to be very different from atherosclerosis
in individuals without diabetes type 2, although certain diabetes-
specific factors could contribute to pro-atherogenic immune acti-
vation and thus aggravate atherosclerosis and risk of CVD. In dia-
betes, reduction of endothelial NO-levels, systemic hyperglycemia
if uncontrolled, generation of reactive oxygen species, oxidative
stress, and increased LDL-oxidation, formation of AGEs, and
increased circulating free fatty acids are factors that add to ather-
osclerosis and CVD risk. Potential triggers of immune activation
in atherosclerosis in the general population (as well as among
diabetics) include OxLDL and other LDL modifications and corre-
sponding antibodies, possibly infections, high levels of heat shock
protein antibodies, and low levels of natural antibodies as anti-PC.
Clinical trials and other studies of immune-modulatory and anti-
inflammatory treatment in atherosclerosis and CVD are currently
conducted but until such treatments are proven to be effective in
humans, the exact role of immune reactions and inflammation in
human atherosclerosis with or without type 2 diabetes remains to
be clarified.
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